WCN25-608 FABRY DISEASE NEPHROPATHY: BIOMARKERS IN PATIENTS ON ENZYME REPLACEMENT THERAPY

WCN25-608 FABRY DISEASE NEPHROPATHY: BIOMARKERS IN PATIENTS ON ENZYME REPLACEMENT THERAPY

Saved in:

Bibliographic Details
Main Authors:	Fernando Perretta, Juan Politei, Santiago Alonso, Gustavo Cabrera, Marcela Pereyra
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S246802492402669X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Fabry Disease: An Update Based on Evidence and Experience
by: J. Politei, et al.
Published: (2025-06-01)

Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort
by: Sebastián Jaurretche, et al.
Published: (2024-01-01)

Current status of the immunogenicity of enzyme replacement therapy in fabry disease
by: Jorge F. Gómez-Cerezo, et al.
Published: (2025-05-01)

Fabry nephropathy. Urinary expression of podocyte proteins mRNA and microRNAs in non-albuminuric patients
by: Sebastián Jaurretche, et al.
Published: (2024-07-01)

Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.
by: Regina El Dib, et al.
Published: (2017-01-01)

Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease
by: Malte Lenders, et al.
Published: (2025-02-01)

Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease
by: V. I. Ignatyeva, et al.
Published: (2019-01-01)

WCN25-2987 2 CASES WITH IGM NEPHROPATHY
by: Nihal Bashir, et al.
Published: (2025-02-01)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors.
by: Maarten Arends, et al.
Published: (2017-01-01)

Günay, Ü. (2000). Din sosyolojisi. Ankara: İnsan, 608s.
by: Sevgi SAVCI BAHÇEKAPILI
Published: (2018-06-01)

Case Report: Diagnostic challenges in Fabry disease: misinterpreted obstructive hypertrophic cardiomyopathy and the role of enzyme replacement therapy
by: Weili Cheng, et al.
Published: (2024-11-01)

WCN25-3861 Is it Membranous nephropathy in a case of Primary APLA?
by: Rahul Sai Gangula, et al.
Published: (2025-02-01)

WCN25-925 A RARE CASE OF AN INHERITED CRYSTALLINE NEPHROPATHY
by: Jawad Iqbal Rather, et al.
Published: (2025-02-01)

Association of ZNF608 Polymorphisms With House Dust Mite‐Induced Allergic Rhinitis
by: Huiqin Li, et al.
Published: (2025-08-01)

Characterization of the craniofacial abnormalities of the homozygous G608G progeria mouse model
by: Indeevar Beeram, et al.
Published: (2024-11-01)

Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards
by: Roberto Giugliani, et al.
Published: (2025-06-01)

WCN25-1917 EXPANDING THE PHENOTYPIC SPECTRUM OF FABRY DISEASE: A CASE OF RENAL INVOLVEMENT IN A CARDIAC VARIANT
by: Rihem Dahmane, et al.
Published: (2025-02-01)

WCN25-3811 PROGRESSION OF ANTICOAGULANT-RELATED NEPHROPATHY AFTER ANTICOAGULANT THERAPY
by: Sherzod Abdullaev, et al.
Published: (2025-02-01)

WCN25-1435 VISUALIZATION OF THE MESANGIAL-CELL-SURFACE AUTOANTIGENS IN IGA NEPHROPATHY
by: Kazuaki Mori, et al.
Published: (2025-02-01)

WCN25-4122 Rituximab in Primary Membranous Nephropathy- three years outcome
by: Prabjot Kaur Johal, et al.
Published: (2025-02-01)

WCN25-1964 PULMONARY HEMORRHAGES IN A PATIENT WITH Ig A NEPHROPATHY
by: Alok Kumar, et al.
Published: (2025-02-01)

WCN25-4525 IGA NEPHROPATHY CLINICOPATHOLOGICAL ASSOCIATION WITH MEST-C SCORING
by: Meghana Rao C, et al.
Published: (2025-02-01)

P608: Perspectives from an Asian population regarding reproductive carrier screening implementation
by: Yasmin Bylstra, et al.
Published: (2025-01-01)

Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down‐Regulation of Mannose‐6‐Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy
by: Andrea Frustaci, et al.
Published: (2025-02-01)

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy
by: Uma Ramaswami, et al.
Published: (2025-06-01)

WCN25-2296 GENDER EQUITY FOR RENAL REPLACEMENT THERAPIES IN INDIA
by: Deepa Usulumarty, et al.
Published: (2025-02-01)

WCN25-1709 Salivary and Urinary Metabolomics Study in IgA Nephropathy Patients
by: Rümeyza Kazancıoğlu, et al.
Published: (2025-02-01)

WCN25-3843 IT IS NOT ALWAYS DIABETIC NEPHROPATHY: A CASE REPORT OF FIBRILLARY GLOMERULONEPHRITIS
by: Reima Almarshoodi, et al.
Published: (2025-02-01)

WCN25-1092 A STUDY OF CLINICOPATHOLOGICAL SPECTRUM AND OUTCOME OF PRIMARY MEMBRANOUS NEPHROPATHY
by: Muzamil ahmad wani, et al.
Published: (2025-02-01)

WCN25-4036 Improved Outcomes with an Additional Rituximab Dose in Primary Membranous Nephropathy
by: Vinod Kumar, et al.
Published: (2025-02-01)

WCN25-851 A RARE CASE OF OXALATE NEPHROPATHY ASSOCIATED WITH CARCINOID SYNDROME
by: Harshil Fichadiya, et al.
Published: (2025-02-01)

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
by: Uptal Patel, et al.
Published: (2025-02-01)

WCN25-4271 UNVEILING DIABETIC FIBRILLOSIS: CLINICAL AND ULTRASTRUCTURAL CORRELATIONS IN DIABETIC NEPHROPATHY
by: Avinash Thakur, et al.
Published: (2025-02-01)

WCN25-1449 FAMILIAL IGA NEPHROPATHY: A PERPLEXING CONUNDRUM IN A FAMILY
by: MANJARI BHAT, et al.
Published: (2025-02-01)

WCN25-4468 NELL-1 POSITIVE MEMBRANOUS NEPHROPATHY: FAIR IS NOT ALWAYS FAIR!
by: AMIT PASARI, et al.
Published: (2025-02-01)

The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type
by: Shuangshuang Wu, et al.
Published: (2017-06-01)

WCN24-1266 NEWLY DETECTED MISSENSE VARIANT IN FABRY DISEASE
by: María Navarro de la Chica, et al.
Published: (2024-04-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-4245 A CASE SERIES OF CONCURRENT IGA NEPHROPATHY AND ANTI- GBM DISEASE
by: Priyangani Lohia, et al.
Published: (2025-02-01)

WCN25-3234 FINRENONE IN DIABETIC NEPHROPATHY: REAL-WORLD EXPERIENCE FROM CENTRAL INDIA
by: Vijay Jeyachandran, et al.
Published: (2025-02-01)